Lhasa Limited shared knowledge shared progress



23 July 2020

2020 Webinar: Controlling a cohort - Understanding the risk of nitrosamines within drug substance synthesis


OPRD graphic 800x369

In this webinar, Dr. Michael Burns, Senior Scientist at Lhasa presented on the topic of, understanding the risk of nitrosamines in drug substance synthesis.

Risk assessments for nitrosamines within marketed drugs must be completed by October 2020, generating a significant challenge for the pharmaceutical industry. Identifying conditions which are favourable to nitrosamines formation represents a key area of knowledge for the pharmaceutical industry and regulatory bodies alike. The use of purge arguments, utilising the scientific understanding of process chemists involved in their manufacture presents a valuable tool to enable a rapid evaluation of risk within drug syntheses. Understanding the potential and limitations for purge of nitrosamines through reactivity constitutes a significant element of potential purge, was also discussed within this presentation. 

If you missed this event, both the presentation slides and a recording are available at the bottom of this page.


You might be interested in reading about a related webinar, "Do all nitrosamines pose a significant level of genotoxic risk?" - read more here.

  • Headline Event (shown first above featured)

  • Featured Event

Back to events

© 2023 Lhasa Limited | Registered office: Granary Wharf House, 2 Canal Wharf, Leeds, LS11 5PS, UK Tel: +44 (0)113 394 6020
VAT number 396 8737 77 | Lhasa Limited is registered as a charity (290866)| Company Registration Number 01765239 (England and Wales).